A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174).

被引：1

作者：

Eads, Jennifer Rachel

Weitz, Michelle

Gibson, Michael K.

Rajdev, Lakshmi

Khullar, Onkar, V

Lin, Steven H.

Gatsonis, Constantine

Wistuba, Ignacio Ivan

Sanjeevaiah, Aravind

Benson, Al Bowen

Bahary, Nathan

Spencer, Kristen Renee

Saba, Nabil F.

Hamilton, Stanley R.

Staley, Charles A.

Chakravarthy, Anuradha Bapsi

Wong, Terence Z.

O'Dwyer, Peter J.

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Vanderbilt Univ, Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA

[4] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Brown Univ, Providence, RI 02912 USA

[8] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[9] Northwestern Med, Chicago, IL USA

[10] Univ Pittsburgh, Sch Med, UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[11] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[12] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[13] Duke Univ, Med Ctr, Durham, NC USA

[14] Univ Penn, Div Med Oncol, Philadelphia, PA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

基金：

美国国家卫生研究院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4651

引用

页数：2

共 50 条

[1] A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in-A trial of the ECOG-ACRIN Cancer Research Group (EA2174).
Eads, Jennifer Rachel
Weitz, Michelle
Catalano, Paul J.
Gibson, Michael K.
Rajdev, Lakshmi
Khullar, Onkar
Lin, Steven H.
Gatsonis, Constantine
Wistuba, Ignacio Ivan
Sanjeevaiah, Aravind
Benson, Al Bowen
Bahary, Nathan
Spencer, Kristen Renee
Saba, Nabil F.
Hamilton, Stanley R.
Staley, Charles A.
Chakravarthy, Bapsi
Fisher, George A.
Wong, Terence Z.
O'Dwyer, Peter J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).
Eads, Jennifer Rachel
Graham, Noah
Gibson, Michael K.
Rajdev, Lakshmi
Chakravarthy, Anuradha Bapsi
Khullar, Onkar V.
Lin, Steven H.
Wistuba, Ignacio Ivan
Agarwal, Rajiv
Blazar, Michael
Mehta, Dhaval R.
Al Baghdadi, Tareq
Jin, Ning
Massa, Ryan Campbell
Hamilton, Stanley R.
Staley, Charles A.
Wong, Terence Z.
O'Dwyer, Peter J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma
Ilson, D.
Janjigian, Y. Y.
Shah, M. A.
Tang, L. H.
Kelsen, D. P.
Campbell, J.
Fuqua, L.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[4] Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma.
Ilson, D.
Shah, M. A.
Kelsen, D. P.
Janjigian, Y. Y.
Tang, L. H.
Campbell, J.
Fuqua, L.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[5] Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
Stockton, Shannon
Catalano, Paul
Cohen, Steven J.
Burtness, Barbara A.
Mitchell, Edith P.
Dotan, Efrat
Lubner, Sam J.
Kumar, Pankaj
Mulcahy, Mary F.
Fisher, George A.
Crandall, Theodore L.
Benson, Al
ONCOLOGIST, 2023, 28 (09): : 827 - +
[6] Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer A Trial of the ECOG-ACRIN Cancer Research Group (E5805)
Stein, Mark N.
Chen, Yu-Hui
Carducci, Michael A.
Hudes, Gary R.
Lerma, Pauline M.
Tan, Winston W.
Dalune, Robert
Rowland, Kendrith M.
Kuzel, Timothy M.
DiPaola, Robert S.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (04): : 375 - 381
[7] Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)
Diefenbach, Catherine S.
Jegede, Opeyemi
Ansell, Stephen M.
Steidl, Christian
Natkunam, Yasodha
Scott, David W.
Mehta-Shah, Neha
Amengual, Jennifer E.
Forlenza, Christopher J.
Cole, Peter D.
Bartlett, Nancy L.
David, Kevin A.
Advani, Ranjana H.
Ambinder, Richard F.
Thomas, Sachdev
Ibrahimi, Sami
Kahl, Brad S.
BLOOD, 2023, 142
[8] Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)
Diefenbach, Catherine S.
Hong, Fangxin
David, Kevin A.
Cohen, Jonathon
Robertson, Michael
Advani, Ranjana
Palmisiano, Neil D.
Ambinder, Richard F.
Kahl, Brad S.
Ansell, Stephen
BLOOD, 2016, 128 (22)
[9] Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and prolonged stable disease observed in adenocarcinoma
Ku, Geoffrey Y.
Janjigian, Yelena Yuriy
Shah, Manish A.
Herrera, Jessica
Tang, Laura H.
Fuqua, Louis
Capanu, Marinela
Ilson, David
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[10] A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176).
Roth, Marc Thomas
Catalano, Paul J.
Ciombor, Kristen Keon
Benson, Al Bowen
Yao, Xin
Yaeger, Rona
Salem, Mohamed E.
Morris, Van K.
Henry, David H.
Whisenant, Jennifer G.
O'Dwyer, Peter J.
Eng, Cathy
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →